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AbstrACt
Objective Examine whether glycaemic control varies 
according to sex and whether the latter plays a role in 
modifying factors associated with inadequate glycaemic 
control in patients with type 2 diabetes (T2D) in Brazil and 
Venezuela.
Design, setting and participants This was a cross-
sectional, nationwide survey conducted in Brazil and 
Venezuela from February 2006 to June 2007 to obtain 
information about glycaemic control and its determinants 
in patients with diabetes mellitus attending outpatient 
clinics.
Main outcome measures Haemoglobin A1c (HbA1c) level 
was measured by liquid chromatography, and patients 
with HbA1c ≥7.0% (53 mmol/mol) were considered to 
have inadequate glycaemic control. The association of 
selected variables with glycaemic control was analysed 
by multivariate linear regression, using HbA1c as the 
dependent variable.
results A total of 9418 patients with T2D were enrolled in 
Brazil (n=5692) and in Venezuela (n=3726). They included 
6214 (66%) women and 3204 (34%) men. On average, 
HbA1c levels in women were 0.13 (95% CI 0.03 to 0.24; 
p=0.015) higher than in men, after adjusting for age, 
marital status, education, race, country, body mass index, 
duration of disease, complications, type of healthcare, 
adherence to diet, adherence to treatment and previous 
measurement of HbA1c. Sex modified the effect of some 
factors associated with glycaemic control in patients with 
T2D in our study, but had no noteworthy effect in others.
Conclusions Women with T2D had worse glycaemic 
control than men. Possible causes for poorer glycaemic 
control in women compared with men include differences 
in glucose homeostasis, treatment response and 
psychological factors. In addition, sex modified factors 
associated with glycaemic control, suggesting the need to 
develop specific treatment guidelines for men and women.
IntrODuCtIOn 
Diabetes mellitus (DM) is a chronic condi-
tion characterised by insulin deficiency or 
impaired response to insulin, leading to 
hyperglycaemia.1 DM directly caused an 
estimated 1.5 million deaths in 2012, making 
it the world’s eight leading cause of death 
among both sexes and the fifth leading 
cause among women.2 In Latin America, DM 
is one of the main causes of death among 
the chronic, non-communicable diseases, 
only exceeded by myocardial infarction and 
stroke.3 According to the American Diabetes 
Association (ADA), the most prevalent form 
is type 2 diabetes (T2D), accounting for 
approximately 90% of all cases.4 
People affected by T2D develop hyper-
glycaemia gradually and may only have 
symptoms once their DM is advanced.4 Late 
diagnosis, difficulty in adjusting individual 
treatment and non-adherence to treatment 
can lead to severe complications, such as reti-
nopathy, neuropathy, nephropathy, ampu-
tation and stroke.5 These complications can 
strengths and limitations of this study
 ► The large multicentre sample, providing statistical 
power to examine the effects of many variables and 
to adjust for confounding.
 ► The measurement of haemoglobin  A1c was per-
formed using a reliable method in a central labora-
tory, avoiding problems with lack of standardisation 
reported by other authors.
 ► This study was conducted in health centres, conse-
quently our conclusions may not apply to patients 
with type 2 diabetes who do not seek medical care 
or who have not yet been diagnosed.
 ► Patients’ data were collected through interviews, 
potentially introducing a certain degree of inaccu-
racy for some answers. However, self-reported data 
have been shown to have high agreement with 
medical records for several questions.
 ► The study design, a cross-sectional survey, is limit-
ing because the temporal relationship between the 
exposure and the outcome cannot be determined 
with certainty.
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have a significant impact on the individual and at the 
population level. There is also a financial burden that not 
only has a significant effect on patients and their families, 
but on health systems worldwide. Overall, 12% of global 
health expenditures are directed at DM and consequent 
complications.1
Complications of DM are avoidable and their likelihood 
of developing is directly correlated with level of glycaemic 
control. Evidence from key controlled studies has estab-
lished the importance of tight and sustained glycaemic 
control among patients with DM.6–8 These studies have 
emphasised the central role of managing HbA1c levels 
in these patients, leading professional associations to 
propose targeting haemoglobin A1c (HbA1c) levels in 
the range of 6.5%–7.0% (48–53 mmol/mol).4
It has been shown that women with DM are generally 
less likely to reach target levels of HbA1c and, therefore, 
have more difficulties achieving adequate glycaemic 
control compared with men.9–16 Possible reasons for the 
different outcomes between men and women are differ-
ences in glucose and energy homeostasis (eg, hormones 
and visceral adipose distribution),17 treatment response 
(eg, side effects) and psychological factors (eg, accep-
tance of disease).18 Despite the potential role of sex on 
glycaemic control, currently, there are no specific treat-
ment guidelines for men and women with T2D.
There are few publications in the medical litera-
ture reporting on the factors associated with glycaemic 
control in patients with T2D in South American coun-
tries.19–21 There is also a dearth of studies describing the 
role sex differences may have on these factors.22 Here, 
we combined data collected in two large surveys on the 
prevalence of glycaemic control21 23 to further examine 
whether glycaemic control varies according to sex, 
and whether the latter modifies factors associated with 
glycaemic control in patients with T2D in Brazil and 
Venezuela.
MethODs
study design and centre selection
We used data from two nationwide surveys on the prev-
alence of glycaemic control conducted in Brazil and 
Venezuela from February 2006 to June 2007. Detailed 
information on study design and methods has been 
published elsewhere.23 24 Briefly, the surveys were 
conducted in outpatient diabetes clinics and obtained 
detailed information about glycaemic control and its 
determinants in a large sample of adults with DM in 
Brazil and in Venezuela. Overall, 52 centres participated 
in the study in Brazil (n=20) and Venezuela (n=32). For 
the selection of diabetes centres, we asked the Brazilian 
Diabetes Association and two Venezuelan diabetes asso-
ciations (Venezuelan Endocrinology Society and La 
Federación Nacional de Asociaciones y Unidades de 
Diabetes—FENADIABETES) to identify, in each of the 
regions studied, a minimum of four candidate centres 
from various registries, patient association lists and 
professional information. These centres were to be 
chosen from those with longer experience in epidemio-
logical research and where at least 100 adult patients with 
diabetes were followed per month. They were classified as 
university-affiliated hospitals (20), public general hospi-
tals (15) or private not-for-profit hospitals (17).
study population
A sample of all consecutive patients with DM attending 
each participating clinic during a 30-day period was 
selected. Eligible cases were adults aged ≥18 years who 
had been previously diagnosed by a physician with 
either type 1 diabetes or T2D before the survey (for the 
current analysis, only T2D were included). Patients who 
had participated in an intervention trial in the previous 
3 months and women who reported a history of diabetes 
only during pregnancy were excluded. Each centre was 
asked to recruit at least 150 patients. Overall, the response 
rates were 84%(78%–95%) in Brazil and 92%(85%–98%) 
in Venezuela.
ethical considerations
All patients were informed about the study aims, proce-
dures and risks and signed an informed consent prior to 
inclusion. The study protocol was carried out in accor-
dance with the principles of the Declaration of Helsinki 
as revised in 2000.
Data collection
Data were collected using different strategies: a struc-
tured questionnaire (including self-reported items) and 
a blood sample to measure HbA1c. The information 
on sociodemographic characteristics (ie, age, sex, race, 
marital status and education), DM history, current medi-
cations, self-reported symptoms and comorbid condi-
tions, complications and clinical parameters (ie, fasting 
blood glucose, HbA1c and body mass index (BMI)) were 
gathered using a structured questionnaire. In addition, 
data on factors related to treatment processes, such as 
self-reported adherence to diet and treatment, patient 
perception of treatment convenience and factors related 
to healthcare access (eg, number of consultations in 
the previous year, whether seen by the same physician, 
private or public healthcare) were obtained. Information 
was also collected on self-rated glycaemic control (using a 
scale with five levels: poor, fair, good, very good and excel-
lent) and satisfaction with current diabetes treatment 
(using a single global question: ‘If you were to spend the 
rest of your life with your diabetes treatment the way it is 
today, how would you feel about this? Very satisfied, some-
what satisfied, neither dissatisfied nor satisfied, somewhat 
dissatisfied, or very dissatisfied’).
Patient and public involvement
A round of pilot testing was conducted prior to data 
collection on a sample of volunteer patients (n=30), in 
both Brazil and Venezuela, to assess and improve question 
wording and interviewer performance. The pilot inter-
views were recorded, and then four reviewers listened 
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to each interview and documented potential issues in 
question presentation or comprehension. Health survey 
experts assessed all items for face validity. The individual 
interviews lasted an average 20–25 min, and the sessions 
occurred in a private room. The study questionnaire was 
administered in person by a team of trained and certified 
interviewers (not part of the local centre staff).
Measurement of glycated haemoglobin
A peripheral blood sample was collected for the measure-
ment of HbA1c in every patient. All measurements of 
HbA1c were made by automated high-performance liquid 
chromatography (Variant Turbo-BioRad) in a central 
laboratory for each country. The normal value range was 
4.0%–6.0% (20–42 mmol/mol).
statistical analysis
Patients with HbA1c ≥7.0% (53 mmol/mol) were consid-
ered to have inadequate glycaemic control.4 Initially, a 
descriptive analysis was performed; the factors possibly 
associated with inadequate glycaemic control were eval-
uated using univariate linear regression, with the value 
of HbA1c as the dependent variable. Next, data from 
men and women were fit into multivariate linear regres-
sion models separately, starting with the same set of inde-
pendent variables and using backwards elimination to 
fit the best model. In this step, variables with a value of 
p<0.10 in either regression model (man or woman) were 
kept. Sociodemographic variables (eg, age, marital status, 
education and race) were kept in the model regardless of 
the significance level. To assess for effect modification by 
sex, we checked whether the point estimate of an inde-
pendent variable in the regression model for one sex was 
not included in the respective 95% CI of the same vari-
able in the regression model for the other sex. The statis-
tical analyses were performed using the STATA statistical 
software V.12).
results
A total of 9418 patients with T2D were enrolled in Brazil 
(n=5692) and Venezuela (n=3726). They included 6214 
(66%) women and 3204 (34%) men (table 1). Ages 
ranged from 18 to 98 years; most of the study partici-
pants were married or living with a partner, of white race 
and had completed primary school education or less. 
The distribution of BMI categories among male patients 
showed that 44.5% were overweight and 25.8% were 
obese compared with 36.2% and 35.2% among female 
patients, respectively. Less than one quarter of the study 
participants reported no complications of DM; approx-
imately half reported poor/fair adherence to diet and 
self-rated their glycaemic control as very good/excellent; 
roughly three quarters(73.6%) were either satisfied or 
very satisfied with their current DM treatment.
The prevalence of inadequate glycaemic control was 
74.2% and 73.0% among female and male patients with 
T2D, respectively. The average HbA1c level was higher 
among women (8.8%)(73 mmol/mol) than in men 
(8.6%)(70 mmol/mol) (p=0.002). In the adjusted analysis, 
the average difference between HbA1c levels in women 
and men was 0.13 (95% CI 0.03 to 0.24; p=0.015). Table 2 
shows the results of the multivariate analysis of factors 
potentially associated with glycaemic control according 
to sex. Increasing age in years was associated with better 
glycaemic control in both men and women. Non-white 
race was a predictor of worse control of DM. Subjects with 
a higher level of education (some college) or residing 
in Brazil were more likely to have a lower HbA1c level. 
Regarding BMI, men in the underweight category had 
worse glycaemic control than those of normal weight, but 
this difference was not observed among women. Obesity 
and overweight were predictors of lower HbA1c levels in 
both sexes. Duration of T2D was positively correlated with 
HbA1c in both men and women, as well as the number 
of complications in women with T2D. Men and women 
who sought a private healthcare service to treat their T2D 
in the past 12 months had lower HbA1c levels compared 
with those who used only public clinics. Better adherence 
to diet (self-reported) was also associated with improved 
glycaemic control, while adherence to treatment was not. 
Having had HbA1c measured in the past 12 months was 
associated with better glycaemic control in women, while 
men who perceived their diabetes treatment as conve-
nient, compared with those who did not, were more likely 
to have a lower level of HbA1c. In both men and women, 
self-rated glycaemic control was associated with lower 
levels of HbA1c.
The magnitude of the association between some factors 
(ie, age, race, education, self-reported adherence to diet, 
and self-rated glycaemic control) and glycaemic control 
was similar in both men and women, while for other 
factors (ie, country of residence, BMI, T2D duration, 
number of complications, access to private healthcare, 
HbA1c measurement in the past year and perception of 
treatment convenience), the magnitude of the associa-
tion seemed different for men as compared with women, 
therefore, suggesting that their effect was modified by 
sex.
DIsCussIOn
We found that women with T2D had significantly higher 
HbA1c levels than men, after adjusting for several poten-
tial confounders. Furthermore, our results have shown 
that sex modifies determinants of glycaemic control, 
suggesting that specific treatment guidelines for men and 
women may be helpful. Some demographic and lifestyle 
characteristics might have changed in the study popu-
lation since the data were collected, but the biological 
differences between sexes have likely remained. Thus, the 
correlates identified here might still be present.
Our findings are consistent with those of previous 
studies. In 2002, a survey of 21 277 patients with diabetes 
between the ages of 45 and 64 years in Israel showed 
better glycaemic control in men, despite lower healthcare 
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Table 1 Characteristics (%) of 9418 patients with T2D in Brazil and Venezuela
Men Women
Brazil Venezuela Total Brazil Venezuela Total
n=1904 
(59%)
n=1300 
(41%)
n=3204 
(100%)
n=3788 
(61%)
n=2426
(39%)
n=6214 
(100%)
Age (years)
  18–34 0.7 1.9 1.2 1.1 1.9 1.4
  35–54 27 35 31 27 32 29
  55–64 36 31 34 34 33 34
  ≥65 36 32 35 38 33 36
Marital status
  Married/living with partner 77 71 75 49 47 48
  Single 10 18 13 16 26 20
  Separated/divorced 8 6 7 9 9 9
  Widowed 5 5 5 25 18 22
Race/ethnicity
  White 49 43 46 43 48 45
  Mixed 29 52 39 29 48 37
  Black 10 4 8 14 3 10
  Others 12 0.1 7 14 1.0 9
Education
  Primary school or less 64 42 55 77 59 70
  Middle school/high school 23 37 28 17 29 21
  Some college 13 22 17 6 12 9
  Body mass index (kg/m2)
  Underweight (≤18.5) 1.1 0.5 0.8 1.8 0.9 1.4
  Normal weight (18.6–24.9) 30 27 29 28 25 27
  Overweight (25.0–29.9) 46 43 45 36 37 36
  Obesity (≥30.0) 23 30 26 34 37 35
Patients with HbA1c ≥7.0 (%) 72 75 73 74 75 74
Complications from diabetes
  None 24 24 24 24 21 23
  1 30 30 30 31 29 31
  2 25 26 26 25 28 26
  >3 20 21 21 20 22 21
Self-reported adherence to diet
  Poor 25 25 25 19 21 20
  Fair 32 35 33 34 38 35
  Good 28 30 29 29 32 30
  Excellent 16 10 14 18 9 15
Self-rated glycaemic control
  Poor 6 5 6 7 3 5
  Fair 5 5 5 8 4 6
  Good 42 37 40 42 37 40
  Very good 39 43 40 36 47 40
  Excellent 8 11 9 8 9 8
Continued
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utilisation.9 A study of 229 Swedish primary health-
care centres, enrolling 9375 subjects (5082 men and 
4293 women) with diabetes, found that men had better 
glycaemic control (HbA1c ≤6.5%/48 mmol/mol) than 
women.12 A cross-sectional study including 3849 patients 
with diabetes in the USA in 2003 found that women were 
less likely than men to have HbA1c <7% (53 mmol/mol) 
after adjusting for age, sociodemographic variables and 
clinic site.13 Data from the Health and Retirement Study 
of 1619 adults with T2D in 2010 also showed that women 
had worse glycaemic control compared with men, even 
though women reported better adherence to diet and 
blood glucose self-monitoring behaviours than men.11
In contrast, other studies have found no significant 
relationship between sex and glycaemic control. For 
example, a study of 180 patients with T2D from two 
health clinics in Texas in 2007 found no sex differences 
in glycaemic control, after adjusting for self-management 
behaviours and quality of life indicators, suggesting that 
sex differences in glycaemic control outcomes might be 
related to less perceived social support, less acceptance of 
disease and more difficulty in self-management behaviour 
in women.25 A cross-sectional study in the UK in 2002 of 
10 663 patients with T2D aged 17–98 years5 and another 
one in Canada with 5569 patients26 also found no associa-
tion between sex and HbA1c levels.
Possible causes for poorer glycaemic control in women 
compared with men include differences in regulation of 
glucose homeostasis,17 treatment response and psycho-
logical factors.18 A survey of 201 Pakistani patients with 
T2D living in Manchester, UK, showed that women were 
worse than men in performing glucose self-measure-
ments and in managing persistent hyperglycaemia, and 
consequently, had poorer glycaemic control overall.15 
Salcedo-Rocha et al in Mexico suggested that women had 
several social and economical disadvantages (ie, lower 
education, lower participation in paid work, and reduced 
wages or economic dependence) that might decrease 
their ability to achieve glycaemic control successfully.16 
Women and men differ in the distribution of body fat and 
in hormonal production, both of which are likely to alter 
the risk of developing T2D and its complications. Obesity 
and being overweight are two of the strongest risk factors 
for developing T2D in both sexes,22 and women are even 
more vulnerable, as they have a higher percentage of 
body fat than men.27 In addition, 40% of men with T2D 
have abdominal obesity, compared with 70% of women, 
suggesting a stronger association between T2D and 
abdominal obesity in women than in men.28
Sex hormones not only regulate sex characteristics and 
fertility, but are essential in regulating glucose homeo-
stasis and are responsible for fundamental biological 
differences between men and women.29 30 Testosterone in 
men stimulates lipolysis in adipose tissue, so low testos-
terone levels are associated with abdominal obesity and 
insulin resistance.29 A meta-analysis in 2006 that reviewed 
80 articles examining sex differences in endogenous 
hormones and the risk of T2D found that men with 
higher testosterone levels (15.6–21.0 nmol/L) had a 42% 
lower risk of developing T2D. They found the opposite 
was true for women, for whom, increased androgen levels 
were associated with insulin resistance and an increased 
risk of T2D.31 Oestrogen is the primary female hormone, 
is synthesised in the ovaries in women before meno-
pause and in adipose tissue in both men and women via 
conversion from testosterone.32 In women, the decrease 
in oestrogen levels after menopause occurs concurrently 
with increased elevated blood glucose levels, whereas in 
men, elevated oestrogen levels may be a risk factor for 
insulin resistance.33
There are also metabolic differences between men and 
women in the pharmacodynamics of the medications used 
to treat T2D. Metformin, an oral hypoglycaemic drug, has 
been shown to have more beneficial effects on myocardial 
fatty acid and glucose metabolism in men than in women.34 
Women were found to report more adverse effects than 
men when treated with this medication (15% vs 10%) 
and were also less adherent to treatment.35 Women may 
also be more likely to experience side effects from thiazo-
lidinediones (insulin-sensitising drugs), experiencing 
more hypoglycaemia36 and bone fractures.37 In patients 
treated with insulin, hypoglycaemia is not only more 
Men Women
Brazil Venezuela Total Brazil Venezuela Total
n=1904 
(59%)
n=1300 
(41%)
n=3204 
(100%)
n=3788 
(61%)
n=2426
(39%)
n=6214 
(100%)
Global satisfaction with current treatment
  Very unsatisfied 1.7 2.0 1.8 1.9 1.0 1.6
  Unsatisfied 8 6 7 10 6 8
  Neutral 16 19 17 16 18 17
  Satisfied 61 61 61 59 65 61
  Very satisfied 14 13 14 13 11 12
T2D, type 2 diabetes.
Table 1 Continued 
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common, but also more severe in women.38 This differ-
ence may, in part, be explained by women having lower 
counter-regulatory responses to hypoglycaemia.39 One 
of the reasons for poorer adherence to more intensive 
insulin treatment and other antidiabetic medications in 
women may be due to fear of these side effects.40
Psychological factors, such as depression, stress and 
anxiety, affect men and women differently and potentially 
contribute to poor glycaemic control. A cross-sectional 
study of 8871 subjects in Germany in 2013 showed that 
social class and psychosocial stress were stronger predic-
tors of T2D in women than in men.41 According to a study 
Table 2 Multivariate linear regression of HbA1c level in men and women with T2D in Brazil and Venezuela
Men Women
β
95% CI
P value β
95% CI
P value
Lower 
limit
Upper
limit
Lower
limit
Upper
limit
Age −0.03 −0.04 −0.03 <0.01 −0.03 −0.04 −0.03 <0.01
Married/living with partner (vs other) −0.06 −0.23 0.12 0.54 0.03 −0.09 0.15 0.60
Non-white race (vs white) 0.18 0.02 0.34 0.03 0.14 0.02 0.27 0.02
Education
  ≤4 years Reference Reference
  5–8 years −0.22 −0.46 0.03 0.09 0.09 −0.09 0.27 0.31
  9–11 years −0.17 −0.37 0.02 0.08 −0.04 −0.20 0.12 0.60
  ≥12 years −0.40 −0.64 −0.16 <0.01 −0.34 −0.58 −0.11 <0.01
Venezuela (vs Brazil) 0.45 0.27 0.62 <0.01 0.71 0.57 0.85 0.00
Body mass index (kg/m2)
  Normal weight (18.6–24.9) Reference Reference
  Underweight (≤18.5) 1.40 0.55 2.25 <0.01 0.35 −0.15 0.86 0.17
  Overweight (25.0–29.9) −0.44 −0.62 −0.26 <0.01 −0.22 −0.37 −0.07 <0.01
  Obesity (≥30.0) −0.43 −0.64 −0.22 <0.01 −0.21 −0.36 −0.05 0.01
Duration of disease
  Up to 5 years Reference Reference
  5–9 years 0.77 0.56 0.98 <0.01 0.96 0.79 1.13 <0.01
  ≥10 years 0.97 0.78 1.17 <0.01 1.37 1.22 1.52 <0.01
1 or more complications from diabetes (vs none) 0.03 −0.15 0.22 0.72 0.19 0.04 0.33 0.01
Have used private healthcare in the past 12 mo (vs not) −0.52 −0.94 −0.10 0.02 −0.29 −0.48 −0.09 0.01
Self-reported adherence to diet
  Poor/fair Reference Reference
  Good 0.06 −0.15 0.27 0.56 −0.09 −0.26 0.08 0.32
  Very good −0.15 −0.37 0.07 0.18 −0.21 −0.39 −0.03 0.02
  Excellent −0.26 −0.54 0.01 0.06 −0.22 −0.43 0.00 0.05
Self-reported adherence to treatment
  Poor/fair Reference Reference
  Good −0.10 −0.60 0.41 0.70 −0.50 −0.89 0.10 0.14
  Very good −0.24 −0.73 0.24 0.32 −0.30 −0.68 0.07 0.12
  Excellent −0.15 −0.62 0.32 0.53 −0.25 −0.62 0.12 0.19
HbA1c measured in past 12 mo (vs not) −0.08 −0.26 0.10 0.38 −0.19 −0.33 −0.05 0.01
Perceived treatment as convenient (vs not) −0.20 −0.36 −0.03 0.02 −0.06 −0.19 0.07 0.35
Self-rated glycaemic control
  Poor/fair Reference Reference
  Good −1.05 −1.32 −0.77 <0.01 −0.87 −1.08 −0.67 <0.01
  Very good −1.51 −1.79 −1.22 <0.01 −1.51 −1.73 −1.29 <0.01
  Excellent −1.77 −2.15 −1.39 <0.01 −1.73 −2.02 −1.45 <0.01
HbA1c, haemoglobin A1c; T2D, type 2 diabetes.
Statistically significant values are shown in bold.
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in 2013 by Siddiqui et al, which reviewed the differences 
between men and women in coping with DM, men with 
DM were more satisfied with the management of their 
disease and experienced less depression and anxiety, 
compared with women with DM.42 Women with T2D were 
also found to have a higher prevalence of depression than 
women without T2D.43
Given that women tend to have worse control of their 
T2D, it is important to assess whether determinants of 
glycaemic control affect men and women differently. 
Sex modified the effect of some factors associated with 
glycaemic control in patients with T2D in our study but 
had no noteworthy effect in others. Patients with T2D 
living in Venezuela had worse glycaemic control than 
those living in Brazil. Healthcare disparities between 
these countries may account for this difference, and 
our results suggest that women are affected by these 
inequalities to a higher extent than men. The relation-
ship between BMI and glycaemic control was also modi-
fied by sex. It is plausible that differences of body fat 
distribution in men and women may lead to a different 
impact on outcomes of glycaemic control.27 Predic-
tors of worse glycaemic control (eg, longer duration 
of disease and presence of complications) also seemed 
to affect women to a higher degree than men. Meno-
pause predisposes women to hyperglycaemia33 44 and 
is more prone to drug side effects.34 Therefore, they 
may be more affected by diabetes duration and related 
complications. Predictors of better glycaemic control 
were modified by sex in different ways. While access to 
private care and perception of treatment as convenient 
seemed to have a greater effect in men as compared 
with women, the opposite was observed for another 
predictor of better glycaemic control (HbA1c measure-
ment in the past year). More studies are warranted to 
better assert these findings.
This study had limitations. It was conducted in health 
centres, consequently our conclusions may not apply 
to patients with T2D who do not seek medical care or 
who have not yet been diagnosed. Patients’ data were 
collected through interviews, potentially introducing a 
certain degree of inaccuracy for some answers. However, 
self-reported data have been shown to have high agree-
ment with medical records for several questions, such as 
type of diabetes, family history of diabetes, therapeutic 
regimen and disease complications.45 Finally, the study 
design, a cross-sectional survey, is limiting because the 
temporal relationship between the exposure and the 
outcome cannot be determined with certainty. The 
strengths of this study are the large multicentre sample, 
providing statistical power to examine the effects of many 
variables and to adjust for confounding. Another merit 
was the collection of data by trained and certified inter-
viewers, who were not part of the staff at the study centres, 
avoiding patients feeling uncomfortable about truthfully 
reporting on adherence to diet or treatment. Last, the 
measurement of HbA1c was performed using a reliable 
method in a central laboratory.
COnClusIOns
We have shown that women with T2D had worse glycaemic 
control than men. In addition, sex modified factors asso-
ciated with glycaemic control suggesting the need of 
specific treatment guidelines for men and women. These 
data may be helpful to improve strategies and policies 
aimed at minimising the complications of T2D in men 
and women with T2D. Longitudinal studies are warranted 
and may help elucidate whether the factors we found to 
be associated with higher HbA1c levels are indeed caus-
ally related to poor glycaemic control.
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